Consensus guidelines from experts appointed by the Myasthenia Gravis Foundation of America (MGFA) indicate thymectomy is an elective procedure and should be performed when a patient is stable and ...

Most generalized MG patients have ocular symptoms at presentation, which progress and cause generalized MG involving the ...

A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...

The FDA has approved the CD19+ B-cell targeted therapy inebilizumab-cdon (Uplizna, Amgen) for the treatment of adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine ...

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new indication for its monoclonal antibody Uplizna. Thursday, the FDA greenlighted ...

Please provide your email address to receive an email when new articles are posted on . FDA approves inebilizumab-cdon for adults with anti-acetylcholine receptor and anti-muscle specific tyrosine ...

In the overall population, inebilizumab demonstrated a statistically significant improvement in MG-ADL total score compared with placebo. The Food and Drug Administration (FDA) has approved Uplizna ® ...

MG Lexicon will help patients and medical professionals communicate and share common information concerning the rare autoimmune, neuromuscular disease myasthenia gravis BOSTON, Dec. 5, 2025 ...

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically ...

Albert Stowell's family thought he was having a stroke. It was Easter dinner 2014, and they were all gathered around the table when he started slurring his words. A trip to the emergency room and a CT ...

Treatment with cemdisiran was associated with a statistically significant improvement in MG-ADL total score compared with placebo. Topline results were announced from a phase 3 trial evaluating ...

1 Neurology Department, National Reference University Hospital, N’Djamena, Chad. 2 Neurology Department, Amirou Boubacar Diallo National Hospital, Niamey, Niger. 3 Ibrahima Pierre Ndiaye Neuroscience ...